M&A trends in 2019: Will the biotech bubble burst?

Though the M&A storm has calmed down slightly, 2019 should be another active year for life sciences dealmaking — particularly in the biotech, payer, outsourced services and healthcare IT arenas, according to some major investment bankers presenting at the Forbes Healthcare Summit in New York.